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Peri-operative pulse oximetry in low-income countries: a cost–
effectiveness analysis
Samantha L Burn,a Peter J Chilton,a Atul A Gawandeb & Richard J Lilfordc
Introduction
The pulse oximeter is a non-invasive medical device that moni-
tors oxygen saturation and pulsation. When used continu-
ously during surgery, it can provide early warning of hypoxia, 
hypovolaemia and impending cardiac arrest. Since oximetry 
can warn of problems such as misplaced endotracheal tubes 
– which can readily be rectified – the World Federation of 
Societies of Anaesthesiologists recommends its routine use 
for every patient undergoing anaesthesia in the world.1,2 The 
World Health Organization (WHO) includes pulse oximetry as 
a component of its Surgical Safety Checklist, which is recom-
mended for use in every operating theatre.1 However, it has 
recently been estimated that pulse oximetry is unavailable in 
51–70% of operating theatres in low-income countries,3 partly 
because of the high purchase cost of a standard commercial 
tabletop pulse oximeter – approximately 1000 United States 
dollars (US$).4 The Lifebox oximetry project, which cur-
rently operates alongside the WHO Safe Surgery Saves Lives 
initiative, provides a hand-held pulse oximeter for low- and 
middle-income countries that costs US$ 250.4 However, even 
this smaller sum is a considerable investment for resource-
constrained settings. Furthermore, because no evidence of 
the cost–effectiveness of pulse oximetry for peri-operative 
monitoring in low-income countries has yet been published, 
it is not clear how oximetry should be prioritized among the 
many cost–effective interventions available.5 In this paper, 
we conducted a cost–effectiveness analysis of pulse oximetry 
– compared with no peri-operative monitoring – for patients 
undergoing surgery in low-income countries. This study is 
based on a synthesis of data from previously published studies 
from a large number of different countries. While the group of 
low-income countries is heterogeneous, the analysis presented 
here is readily adaptable to specific national contexts.
Methods
We investigated the equivalent annual costs of purchasing and 
maintaining pulse oximeters, as well as the costs of increased 
oxygen flow used to treat any hypoxic episodes identified by 
oximetry. We took a health services perspective. In quantifying 
the health benefits of peri-operative oximetry, we considered 
the number of disability-adjusted life-years (DALYs) averted 
by using pulse oximetry to reduce the incidence of fatal intra-
operative hypoxic episodes. We ignored non-fatal cases of 
hypoxic brain injury. Base case analysis was conducted using 
version 3.0.1 of the R software package (R Foundation for 
Statistical Computing, Vienna, Austria) and Microsoft Excel 
2010 (Microsoft, Redmond, USA) and sensitivity analysis us-
ing the TreeAge Pro 2013 software package (TreeAge Software 
Inc., Boston, USA).
Costs
We only considered oximeters that met the IEC 60601–1, 
ISO 9919:2005 or ISO 80601–2–61:2011 international stan-
dards for safety and performance. There are two main types 
of stand-alone pulse oximeter designed for peri-operative 
use: the standard commercial tabletop oximeter and a less 
expensive hand-held device with similar functionality but a 
more portable and durable design and a rechargeable battery.6 
Objective To evaluate the cost–effectiveness of pulse oximetry – compared with no peri-operative monitoring – during surgery in low-
income countries.
Methods We considered the use of tabletop and portable, hand-held pulse oximeters among patients of any age undergoing major surgery 
in low-income countries. From earlier studies we obtained baseline mortality and the effectiveness of pulse oximeters to reduce mortality. 
We considered the direct costs of purchasing and maintaining pulse oximeters as well as the cost of supplementary oxygen used to treat 
hypoxic episodes identified by oximetry. Health benefits were measured in disability-adjusted life-years (DALYs) averted and benefits and 
costs were both discounted at 3% per year. We used recommended cost–effectiveness thresholds – both absolute and relative to gross 
domestic product (GDP) per capita – to assess if pulse oximetry is a cost–effective health intervention. To test the robustness of our results 
we performed sensitivity analyses.
Findings In 2013 prices, tabletop and hand-held oximeters were found to have annual costs of 310 and 95 United States dollars (US$), 
respectively. Assuming the two types of oximeter have identical effectiveness, a single oximeter used for 22 procedures per week averted 
0.83 DALYs per annum. The tabletop and hand-held oximeters cost US$ 374 and US$ 115 per DALY averted, respectively. For any country 
with a GDP per capita above US$ 677 the hand-held oximeter was found to be cost–effective if it prevented just 1.7% of anaesthetic-related 
deaths or 0.3% of peri-operative mortality. 
Conclusion Pulse oximetry is a cost–effective intervention for low-income settings.
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The oximeter distributed by the Lifebox 
charity is of the second type. 
Costs are given in 2013 prices 
and discounted at 3% per year – as 
recommended in version two of the 
Disease Control Priorities in Developing 
Countries5 and the WHO-CHOICE7,8 
guidelines for evaluation of the cost–ef-
fectiveness of health interventions in 
developing countries. Domestic taxes 
were excluded. We assumed that no 
extra operations would be carried out 
as a result of introducing oximetry and 
that no extra clinical staff time would be 
required. We included supplementary 
oxygen9 resulting from an increase in the 
incidence of detected hypoxia10 when 
oximetry is used.
Health benefits
Most of the published data on the per-
formance of oximeters relate to tabletop 
oximeters. However, the low-cost hand-
held oximeter distributed by Lifebox has 
recently been found to perform as well as 
tabletop oximeters that have been pro-
duced by major manufacturers, made 
commercially available in the United 
States of America.11 For our analysis, we 
therefore assumed that the effectiveness 
of the hand-held devices in averting 
peri-operative death was identical to 
that of the tabletop devices.
Lifebox has found that the oxim-
eters it distributes can be used for 25–30 
surgeries per week.12 For our analysis, we 
assumed that each of the oximeters we 
investigated was used at about 80% of 
these frequencies8 – i.e. in 22 procedures 
per week.
Baseline mortality
We did a systematic search to identify 
systematic reviews of anaesthetic-re-
lated and total peri-operative mortal-
ity including studies from low-income 
countries published between 1 Janu-
ary 1990 and 31 December 2012. The 
search terms used included variants of 
anaesthetic, surgery, operation, intra-
operative, peri-operative, peri-surgical, 
death, mortality and survival (Box 1). 
We searched the following databases: 
MEDLINE via OvidSP, EMBASE via 
OvidSP, Scopus, the Cochrane Database 
of Systematic Reviews, the Database 
of Abstracts of Reviews of Effects, the 
Health Technology Assessment Data-
base and the International Prospective 
Register of Systematic Reviews. We 
used the Centre for Reviews and Dis-
semination filter (strategy 2.1) to iden-
tify systematic reviews.13 No language 
restrictions were applied.
Two systematic reviews of anaes-
thetic-related and total peri-operative 
mortality that included studies from 
low-income countries were identi-
fied.14,15 Since it was the more recent of 
the two reviews and included a formal 
meta-analysis, we used the study by 
Bainbridge et al.14 to parameterize our 
cost–effectiveness estimates. This study 
found that total peri-operative mortality 
in low-income countries – i.e. countries 
with a human development index be-
low 0.8 – was 2445 deaths per million 
procedures.14 They also found that, in 
low-income countries, problems in the 
administration of anaesthesia – e.g. 
oesophageal intubation or kinking of 
the endotracheal tube – were the sole 
or contributing cause of 467 deaths per 
million procedures. We took 467 deaths 
per million procedures as our baseline 
for deaths that were potentially prevent-
able by oximetry. However, this may be 
a conservative estimate, since oximetry 
could also provide an early warning 
of a deterioration in the patient’s un-
derlying condition that was unrelated 
to anaesthesia. Also, as oximetry may 
have been used in one or more of the 
studies investigated by Bainbridge et al., 
467 deaths per million procedures may 
represent an underestimate of mortality 
in the absence of oximetry.
For robustness, we replicated the 
search procedure used by Bainbridge 
et al.14 to identify any recent studies of 
relevance that had been published on 
or before 30 December 2012. We found 
no new studies relating to low-income 
countries. We also examined the six 
studies that were excluded by Bainbridge 
et al. because of small sample size16,17 or 
because they pertained exclusively to 
one clinical area.18–21 Two of these stud-
ies contained estimates of anaesthetic-
related avoidable mortality for a general 
population, which were 1985 and 7500 
deaths per million procedures. In our 
sensitivity analysis, we therefore con-
sidered values of anaesthetic-related 
avoidable mortality that varied from 253 
deaths per million procedures – i.e. the 
lowest estimate from the studies inves-
tigated by Bainbridge et al.14 – to 7500 
deaths per million procedures.
Effectiveness in reducing mortality
The available data on the effectiveness 
of pulse oximetry come from obser-
vational studies – e.g. before-and-after 
studies or critical incident reports – and 
randomized controlled trials. In this 
context, such studies and trials are im-
perfect. Since peri-operative deaths are 
extremely rare, none of the relevant ran-
domized controlled trials is adequately 
powered to detect the effects of oximetry 
on the probability of such deaths.10,22 The 
relevant observational studies do not al-
low cause–effect statements to be made 
with confidence since such studies are 
confounded by temporal changes that 
are unrelated to oximetry.23,24
We did a systematic search to iden-
tify systematic reviews of the effective-
ness of oximetry in preventing hypoxia 
and peri-operative death published be-
tween 1 January 1990 and 31 December 
2012 (Box 1). We searched the same set 
of databases as for baseline anaesthetic-
related mortality. We identified one sys-
tematic review of randomized controlled 
trials of the effectiveness of pulse oxim-
etry, in which the authors concluded that 
pulse oximetry reduces the incidence 
of hypoxaemia by 33–67% but appears 
Box 1. Search strategy for key parameters published in systematic reviews
Baseline anaesthetic-related mortality
1. Surgery[Mesh] OR surg* OR operat* OR perioperat* OR peri-operat* OR intraoperat* OR 
intra-operat* OR “in theatre”
2. Anesthesia[Mesh] OR anesth* OR anaesth* OR peri-anesth* OR perianesth* OR post-anesth* 
OR post-anaesth*
3. Death OR mortalit* OR morbidit* OR survival*
4. (#1 OR #2) AND #3
Effectiveness of pulse oximetry in reducing hypoxic episodes and/or peri-operative mortality
1. Surgery[Mesh] OR surg* OR operat* OR perioperat* OR peri-operat* OR intraoperat* OR 
intra-operat* OR “in theatre”
2. Oximet* OR oxymet*
3. Death OR mortalit* OR morbidit* OR survival*
4. Anoxia[Mesh] OR anox* OR hypox*
5. (#1 AND #2) AND (#3 OR #4)Bull World Health Organ 2014;92:858–867| doi: http://dx.doi.org/10.2471/BLT.14.137315 860
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to have no statistically significant effect 
on mortality.22 To check the robustness 
of this result, we reviewed the studies 
that were excluded because they were 
not randomized.22 These excluded stud-
ies25–27 that indicated a similar oximetry-
attributable decline in hypoxaemia to 
that observed in the included studies. 
Other observational data indicate that 
anaesthetic-related mortality in high-
income countries has declined by 64% 
since the 1980s, as various monitoring 
standards, including pulse oximetry, 
have been widely implemented.14,28,29
While much of the evidence assem-
bled relates to high-income countries, 
the results of a before-and-after study 
conducted in the Republic of Moldova 
Table 1.  Costs of purchasing, maintaining and repairing pulse oximeters




Cost of purchase, shipping 
and internal transport, US$
1065 (600–3000) 250 (250–280) Lifebox product information4
Life-span, years 6 (4–8) 8 (6–10) Expert opinion
Annuitized maintenance 
costs, including those for 
replacement probes and 
batteries, US$b
34 (17–85) 18 (15–31) Probes for tabletop device replaced every 2 (1–3) years at 
a cost of US$ 100.40,c Probes for hand-held device replaced 
every 2 (1–3) years at a cost of US$ 254 and batteries for 
hand-held device replaced every year at a cost of US$ 104
Annuitized repair costs, US$ 45 (30–60) 6 (2–13) 15% (10–20%) chance of breakage of a tabletop device each 
year, at a total cost per year of US$ 355 including shipping.40,c 
5% (1–10%) chance of breakage of hand-held device 
each year, at a total cost per year of US$ 65 during the first 
2 years – when the device is under warranty – and US$ 138 
thereafter4
Annual cost of treating 
additional hypoxic episodes 
identified by pulse 
oximetry, US$
35 (17–52) 35 (17–52) Incidence of hypoxia is 7.9% with pulse oximetry and 
0.4% without oximetry.10 If hypoxia is detected, oxygen 
flow increased by 8 litres/min for 10 minutes,c at a cost of 
US$ 0.40 per additional hypoxic episode detected9
Total equivalent annual 
cost, US$
310 95 Authors’ calculations. Uncertainty explored in sensitivity 
analysis
US$: United States dollars.
a  All costs are shown adjusted to 2013 values, assuming 3% inflation per year.
b  Excludes share of general overhead costs attributable to use of pulse oximetry – i.e. costs of cleaning and electricity.
c  Value partly or entirely based on expert opinion.
Table 2.  Effectiveness and cost–effectiveness of pulse oximeters





related mortality, deaths 
per million operations 
requiring general 
anaesthesia
467 (253–7500) 467 (253–7500) Systematic review of anaesthetic-related mortality14
Anaesthetic-related deaths 
averted by oximetry, %
10 (3–50) 10 (3–50) Authors’ estimates based on intermediate outcomes 
from systematic review of randomized control trials22 and 
observational data14,28,29
Discounted DALYs per 
death avoideda
15.5 (10–30) 15.5 (10–30) Authors’ calculation based on approximation of age 
distribution of patients undergoing surgery36 and health-
adjusted life expectancy by age35
Number of times each 
oximeter used per week
22 (20–30) 22 (20–30) Assumed 80% utilization8 of maximum capacity of 25–30 
operations per week12
Discounted DALYs averted 
per year of oximeter use
0.83 0.83 Authors’ calculation
Equivalent annual cost of 
oximeter, US$b
310 95 See Table 1
Cost per DALY averted, 
US$c
374 115 Authors’ calculation
DALY: disability-adjusted life-year; US$: United States dollars.
a  Based on region-specific life-tables.
b  From Table 1, in 2013 values.
c  In 2013 values.Bull World Health Organ 2014;92:858–867| doi: http://dx.doi.org/10.2471/BLT.14.137315 861
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indicated that the introduction of pulse 
oximetry – along with the entire WHO 
Surgical Safety Checklist – reduced 
the number of hypoxaemic episodes 
lasting at least two minutes by 44%.30 
Another before-and-after study found 
that introduction of the checklist led to 
a 60% reduction in total peri-operative 
mortality over four study sites in low-
income countries.31 However, the check-
list contains several other items known 
to be associated with improved safety 
outcomes, so these reductions are prob-
ably not attributable to oximetry alone.
We selected 50% as the upper plau-
sible limit for effectiveness of oximetry 
in reducing anaesthetic-related deaths, 
since this is the figure obtained us-
ing the surrogate outcome of hypoxic 
episodes in the randomized control 
trials described above.10,22 This a highly 
optimistic value, since surrogate out-
comes are notorious for overestimating 
clinical benefit.32–34 We therefore used 
50% as an upper bound for effective-
ness. For a lower bound we selected a 
2% improvement in anaesthetic-related 
mortality, to represent a very pessimistic 
estimate given the randomized control 
trials and observational evidence cited 
above. For the base case we used effec-
tiveness of 10%, founded on the nature 
of the available evidence and based on 
discussion with our advisors. Since there 
is considerable uncertainty surrounding 
these values, we conducted extensive 
sensitivity analysis.
Disability-adjusted life-years averted
Health benefits were measured in 
DALYs averted, with uniform age-
weighting and discounting at 3% per 
annum. DALYs were calculated using 
actual life expectancy rather than life 
expectancy for a hypothetical reference 
group.5 Using pooled health-adjusted 
life expectancy tables for the Eastern 
Sub-Sahara Global Burden of Disease re-
gion35 and a probability density function 
of the ages of patients undergoing major 
surgery in Mozambique, Uganda and 
the United Republic of Tanzania,36 we 
calculated that 15.5 DALYs are averted 
per anaesthetic-related death avoided.
We assumed that the sex distribu-
tion of patients was the same as that of 
the relevant national population. We 
also assumed that, in all cases of averted 
death, a patient’s health-adjusted life ex-
pectancy did not differ from that of the 
general population and that the benefits 
of pulse oximetry were too small to alter 
overall national life expectancies.
Cost–effectiveness thresholds
We used two common types of cost–ef-
fectiveness thresholds for health inter-
ventions in low-income countries:37 the 
absolute thresholds used by the World 
Bank in the World development report 
199338 and the thresholds – defined 
relative to the corresponding gross do-
mestic product (GDP) per capita – used 
by WHO-CHOICE.7 According to the 
World development report 1993, inter-
ventions that, in 1993, cost no more than 
US$ 25 and US$ 150 per DALY averted 
could be considered highly attractive 
and attractive, respectively. Assuming 
3% inflation per year, the corresponding 
thresholds for the year 2013 would be 
US$ 45 and US$ 271. WHO-CHOICE 
considered interventions that, per DALY 
averted, cost no more than one and three 
times the relevant GDP per capita to be 
very cost–effective and cost–effective, 
respectively.7 For the group of low-
income countries as a whole, US$ 677 
and US$ 2031 are one and three times 
the 2013 GDP per capita, respectively.39
Results
Our cost and cost–effectiveness esti-
mates are summarized in Table 1 and 
Table 2, respectively. In the base case 
– comparing each type of oximeter 
with no monitoring of oxygen satura-
tion and assuming both the tabletop 
and hand-held pulse oximeters reduce 
anaesthetic-related mortality by 10% 
– the costs per DALY averted were 
US$ 374 for the tabletop pulse oximeter 
and US$ 115 for the hand-held oximeter. 
Since we assume in this analysis that the 
effectiveness of the two types of oximeter 
is identical and the hand-held oximeter 
is less costly, the hand-held oximeter 
dominates the tabletop oximeter. The 
cost–effectiveness of the hand-held 
oximeter fell below the very cost–effec-
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Threshold for cost–effective intervention
Threshold for very cost–effective intervention
Threshold for attractive intervention
Threshold for highly attractive intervention
DALY: disability-adjusted life-year; GDP: gross domestic product; US$: United States dollars.
Note: The cost–effective thresholds were for the year 2013. Attractive interventions were based on the 
World development report 1993.38 Cost–effective interventions were based on World Health Organization 
guidelines, with very cost–effective and cost–effective interventions below one (US$ 677) and three 
(US$ 2031) times the GDP per capita for the group of low-income countries, respectively7,39 
The base case, lower bound and upper bound are our own estimates of the proportions of anaesthetic-
related deaths that could be averted by the routine use of pulse oximetry.Bull World Health Organ 2014;92:858–867| doi: http://dx.doi.org/10.2471/BLT.14.137315 862
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tive threshold of one times the GDP per 
capita for low-income countries.
The purchase of a hand-held ox-
imeter for each of the 77 000 operating 
theatres globally that currently do not 
have pulse oximeters3 would cost about 
US$ 19.3 million. Using the parameters 
in this paper, we estimate that equipping 
all of these operating theatres with pulse 
oximeters would reduce the global bur-
den of disease by 63 800 DALYs per year.
Sensitivity analyses
Given the paucity of trial data and the 
uncertainty surrounding the effective-
ness of pulse oximetry in averting an-
aesthetic-related mortality, we explored 
the sensitivity of our results to variation 
in the key parameters.
Fig. 1 shows the cost per DALY 
averted as a function of the percentage 
of anaesthetic-related mortality pre-
vented by pulse oximetry. The hand-held 
pulse oximeter falls below the attractive 
threshold for 2013 from the World de-
velopment report 1993, if it prevents 4% 
of anaesthetic-related mortality. It falls 
below the GDP per capita of the group 
of low-income countries if it prevents 
1.7% of anaesthetic-related mortality 
(0.3% of total peri-operative mortal-
ity). The wide variation seen in levels 
of anaesthetic-related and total peri-
operative mortality between settings 
has an impact on the cost–effectiveness 
of pulse oximetry.14,16,17,41 Fig. 2 shows 
the cost of a hand-held pulse oximeter, 
per DALY averted, as a function of 
baseline anaesthetic-related mortality, 
assuming that pulse oximetry prevents 
10% of anaesthetic-related deaths. With 
baseline anaesthetic-related mortalities 
of 25341 and 750017 deaths per million 
operations requiring general anaesthe-
sia, a hand-held pulse oximeter would 
have cost US$ 211 and US$ 7 per DALY 
averted, respectively.
We conducted a basic probabilis-
tic sensitivity analysis by carrying out 
1000 iterations using the parameter 
distributions given in Table 3. The ef-
fectiveness of oximetry in averting 
death was assumed to be independent 
of baseline anaesthetic-related mortal-
ity. Although the median incremental 
cost–effectiveness was US$ 154 per 
DALY averted, the corresponding mean 
cost–effectiveness was much higher – 
US$ 628 – largely because of the small 
number of simulations with extremely 
low baseline mortality and effectiveness. 
The corresponding cost–effectiveness 
acceptability curve (Fig. 3) indicates that 
hand-held pulse oximeters are likely to 
be considered cost–effective – compared 
with no oximetry – with all but the most 
stringent cost–effectiveness threshold. 
Pulse oximetry fell under the WHO 
very cost–effective threshold in 83% of 
the simulations and under the attractive 
cost–effectiveness threshold from the 
World development report 1993 in 62% 
of the simulations. The results of the 
probabilistic sensitivity analysis should 
be interpreted with caution because of 
our uncertainty about the relationship 
between identified hypoxic episodes 
and mortality.
Discussion
Although this study is not entirely 
based on hard evidence from random-
ized controlled trials, our results indi-
cate that pulse oximetry is cost–effec-
tive. Obtaining parameter estimates for 
a decision model is often difficult. In 
this case, the problem was compounded 
by a paucity of evidence relating to use 
of oximetry in low-income settings and 
the very low frequency of the outcome 
of interest. To estimate the effectiveness 
of oximetry in averting peri-operative 
death, it was necessary to extrapolate 
from surrogate outcomes and from 
observational studies in high income 
countries. Another possibility would 
have been to estimate this parameter 
by means of a Bayesian elicitation, but 
the estimate would still have been an 
informed guess. Our approach instead 
was to carry out extensive sensitivity 
analysis. In our base case, the hand-
held pulse oximeter appeared to be 
very cost–effective for low-income 
countries if it prevented just 1.7% of 
anaesthetic-related deaths or 0.3% of 
total peri-operative deaths. It is worth 
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Baseline anaesthetic-related mortality
(deaths per million operations requiring general anaesthesia)
DALY: disability-adjusted life-year; GDP: gross domestic product; US$: United States dollars.
Note: The cost–effective thresholds were for the year 2013. Attractive interventions were based on the 
World development report 1993.38 Cost–effective interventions were based on World Health Organization 
guidelines, with very cost–effective and cost–effective interventions below one (US$ 677) and three 
(US$ 2031) times the GDP per capita for the group of low-income countries, respectively7,39 
The base case,14 lower bound14 and upper bound17 report levels of the baseline anaesthetic-related 
mortality that occurs – or might occur – in the absence of pulse oximetry.Bull World Health Organ 2014;92:858–867| doi: http://dx.doi.org/10.2471/BLT.14.137315 863
Research
Cost–effectiveness of pulse oximetry Samantha L Burn et al.
noting that to detect an improvement of 
this magnitude in total peri-operative 
mortality in a randomized controlled 
trial would require a sample size of 
almost 1.5 billion patients – and such a 
trial will never be conducted. The aim 
of the WHO Global Pulse Oximetry 
Project is to make pulse oximetry more 
widely available is based on best prac-
tice from high-income countries and 
the results of informal analysis1 – rather 
than on an explicit calculation of what 
oximetry would have to achieve to be 
cost–effective.
In this paper, we only considered 
deaths averted by oximetry. Our esti-
mates of the cost–effectiveness of pulse 
oximetry would probably have increased 
if we had also considered non-fatal 
brain damage. Discussions with doc-
tors working in low-income countries 
highlighted several additional points. 
First, pulse oximetry may actually 
reduce overall oxygen use, since flow 
rate can be reduced where saturation 
is adequate. Second, the availability of 
oximetry may change clinical practice. 
For example, only practitioners with ac-
cess to oximetry may be willing to use 
alternatives to general anaesthesia that 
may be safer in some situations – e.g. 
spinal blocks in obstetrics. Third, there 
is a role for oximetry outside the operat-
ing theatre – e.g. in monitoring patients 
in the recovery room and mothers and 
neonates during vaginal delivery, and 
reducing oxygen use in patients with 
pneumonia who are tachypnoeic but 
well saturated.42,43
Our analysis considered only 
stand-alone tabletop and hand-held 
oximeters. A third type of oximeter, the 
fingertip oximeter, is even cheaper than 
the hand-held devices – with a purchase 
cost of US$ 3044 – but is designed only 
for spot-checks in primary care and 
probably has limited usefulness in op-
erating theatres, since it lacks an audible 
tone that changes with oxygen satura-
tion, an alarm to indicate desaturation 
and a plethysmograph display. As well 
as stand-alone pulse oximeters, pulse 
oximetry may be built into other devices 
– e.g. anaesthesia machines or sphyg-
momanometers – or combined with 
electrocardiography or capnography in 
a multivariable monitor.45 In practice 
the choice of which type of oximeter to 
purchase is likely to depend on a variety 
of setting-specific considerations. For 
example, in a setting with only inter-
mittent electricity supply, a standard 
tabletop oximeter would be unsuitable 
because of its inability to function for 
long periods without mains electricity. 
The presence of combined capnography 
or other functionality in an expensive 
unit that can be used for oximetry is 
only valuable if the requisite expertise 
is present.46






Anaesthetic-related mortality, deaths 
per million operations requiring 
general anaesthesia
467 Log–normal µ = 6.0; σ = 0.56 Systematic review, with variance 
increased to take into account higher 
mortality for excluded studies14
Proportion of anaesthetic-related 
deaths averted by pulse oximetry
0.1 Beta α = 1; β = 9 Authors’ estimates based on 
intermediate outcomes from review 
of randomized control trials22 and 
observational data14,28,29
Annual equivalent cost of purchasing 
and maintaining a hand-held pulse 
oximeter, US$ per 1000 operations 
requiring general anaesthesia
83 Log–normal µ = 4.4; σ = 0.81 Authors’ calculation
US$: United States dollars.
















































































































































































































































Cost–effectiveness threshold (US$ per DALY averted)
500 1 000 1 500 2 000 2 500
DALY: disability-adjusted life-year; GDP: gross domestic product; US$: United States dollars.
Note: The cost–effective thresholds were for the year 2013. Attractive interventions were based on the 
World development report 1993.38 Cost–effective interventions were based on World Health Organization 
guidelines, with very cost–effective and cost–effective interventions below one (US$ 677) and three 
(US$ 2031) times the GDP per capita for the group of low-income countries, respectively7,39Bull World Health Organ 2014;92:858–867| doi: http://dx.doi.org/10.2471/BLT.14.137315 864
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生命年 (DALY) 测量健康益处 , 收益和成本每年都折减
3%。我们使用推荐的成本效益阈值 ( 绝对值以及与人
均国内生产总值 (GDP) 对比的相对值 ) 评估脉搏血氧
测量仪是否是具有成本效益的健康干预。我们执行敏
感性分析来测试结果的稳健性。
结果 以2013 年的价格计算 , 台式和手持血氧测量仪年
度成本分别为 310 和 95 美元。假设这两种类型的血氧
测量仪具有相同的效果 , 单个血氧测量仪每周用于 22
台手术过程 , 每年可避免 0.83 个 DALY。台式和手持血
氧测量仪避免一个DALY的成本分别为374和115美元。
研究发现 , 对于任何人均国内生产总值超过 677 美元
的国家 , 手持血氧测量仪仅避免 1.7% 的麻醉相关死亡
或 0.3% 的围手术期死亡率就具有成本效益。
结论 低收入的环境中 , 脉搏血氧测量是一种经济有效
的干预措施。
There is a large body of literature 
relating to cost–effectiveness of health 
interventions in low-income coun-
tries.5,7 Much of this literature relates to 
evaluations of complex interventions 
that are of little value in specific device-
procurement decisions. There is also an 
emerging interest in frugal innovation 
– i.e. the adaptation of existing medi-
cal technologies to make them more 
affordable and more suitable for use in 
low-resource settings.6,40,47 We hope that 
analysis of the type presented here – in 
which the types and grades of device 
available for a particular purpose are 
made explicit – could help bridge the 
gap between the literature on cost–ef-
fectiveness of health interventions and 
the literature on technical specifications 
for devices, allowing decision-makers 
to proceed beyond the prioritization of 
complex interventions to the selection 
of specific devices for different clinical 
settings.46 ■
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صخلم
ةيدودرلما ليلتح :لخدلا ةضفخنلما نادلبلا في ةيلمعلاب ةطيحلما ةترفلا في ضيبنلا جسكأتلا سايق
 مدعب ةنراقم - ضيبنلا جسكأتلا سايق ةيدودرم ريدقت ضرغلا
 نادلبلا  في  ةحارلجا  ءانثأ  -  ةيلمعلاب  ةطيحلما  ةترفلا  في  دصرلا
.لخدلا ةضفخنلما
 يتلا ضيبنلا جسكأتلا سايق ةزهجأ مادختسا ةساردب انمق ةقيرطلا
 ينب ديلاب ةلومحلماو لقنلل ةلباقلاو تلاواطلا حطسأ لىع عضوت
 ىبرك ةحارلج اوعضخو ةيرمع ةئف يأ لىإ نومتني نيذلا ضىرلما
 لىع ةقباسلا تاساردلا نم انلصحو .لخدلا ةضفخنلما نادلبلا في
 جسكأتلا سايق ةزهجأ ةيلاعفو ساسلأا طخ دنع تايفولا لدعم
 ةشرابلما  فيلاكتلا  انسردو  .تايفولا  لدعم  ليلقت  في  ضيبنلا
 لىإ  ةفاضلإاب  اهتنايصو  ضيبنلا  جسكأتلا  سايق  ةزهجأ  ءاشرل
 صقن تابون جلاعل مدختسي يذلا لييمكتلا ينجسكولأا ةفلكت
 دئاوفلا  سايق  متو  .جسكأتلا  سايق  اهدديح  يتلا  ينجسكولأا
 يتلا  زجعلا  ددم  باستحاب  ةححصلما  رمعلا  تاونسب  ةيحصلا
 % 3 ةبسنب اهنم لك في فيلاكتلا ضفخ متو دئاوفلاو ايهدافت مت
 ةيبسنلاو ةقلطلما - ابه صىولما ةيدودرلما تابتع انمدختساو .ًايونس
 جسكأتلا سايق ناك اذإ ام مييقتل - درفلل ليحلما لياجملإا جتانلل
 انذفن ،انجئاتن ةوق رابتخلاو .ةيدودرم اذ ًايحص ًلاخدت ضيبنلا
.ةيساسلحا تلايلتح
 سايق ةزهجلأ ةيونسلا فيلاكتلا نأ 2013 راعسأ قفو ينبت جئاتنلا
 غلبت ديلاب ةلومحلماو تلاواطلا حطسأ لىع عضوت يتلا جسكأتلا
 ةيدودرلما قباطت ضاترفابو .لياوتلا لىع ،ًايكيرمأ ًارلاود 95و 310
 دحاولا جسكأتلا سايق زاهج يدؤي ،جسكأتلا سايق ةزهجأ يعونل
 نم ةنس 0.83 يدافت لىإ ًايعوبسأ ةيلمع 22 في مدختسي يذلا
 غلبتو  .ًايونس  زجعلا  ددم  باستحاب  ةححصلما  رمعلا  تاونس
 تلاواطلا حطسأ لىع عضوت يتلا جسكأتلا سايق ةزهجأ ةفلكت
 لكل ًايكيرمأ ًارلاود 115و ًايكيرمأ ًارلاود 374 ديلاب ةلومحلماو
 ،زجعلا ددم باستحاب ةححصلما رمعلا تاونس نم ايهدافت مت ةنس
 هيف درفلل ليحلما لياجملإا جتانلا ديزي دلب يلأ ةبسنلابو .لياوتلا لىع
 لومحلما جسكأتلا سايق زاهج نأ ينبت ،ًايكيرمأ ًارلاود 677 نع
 تلااح نم طقف % 1.7 يقوت ةلاح في ةيدودرم اذ نوكي ديلاب
 ةترفلا في تايفولا لدعم نم % 0.3 وأ ريدختلاب ةلصلا تاذ ةافولا
.ةيلمعلاب ةطيحلما
 قطانلما في ةيدودرم اذ ًلاخدت ضيبنلا جسكأتلا سايق برتعي جاتنتسلاا
.لخدلا ةضفخنمBull World Health Organ 2014;92:858–867| doi: http://dx.doi.org/10.2471/BLT.14.137315 865
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Résumé
Oxymétrie de pouls périopératoire dans les pays à revenu faible: une analyse de la rentabilité
Objectif Évaluer la rentabilité de l’oxymétrie de pouls par rapport à 
l’absence de surveillance périopératoire lors d’une chirurgie dans les 
pays à revenu faible.
Méthodes Nous avons considéré l’utilisation d’oxymètres de pouls à 
poser et d’oxymètres de pouls portatifs chez des patients de tous âges 
ayant subi une opération chirurgicale importante dans des pays à revenu 
faible. À partir d’études antérieures, nous avons obtenu la mortalité de 
référence et l’efficacité des oxymètres de pouls pour réduire la mortalité. 
Nous avons considéré les coûts directs de l’achat et de l’entretien des 
oxymètres de pouls, ainsi que le coût de l’oxygène supplémentaire 
utilisé pour traiter les épisodes hypoxiques identifiés par oxymétrie. Les 
avantages pour la santé ont été mesurés en espérance de vie corrigée de 
l’incapacité (EVCI) évitée, et les avantages et les coûts ont été actualisés à 
3% par an. Nous avons utilisé les seuils de rentabilité recommandés – à 
la fois de manière absolue et relative par rapport au produit intérieur 
brut (PIB) par habitant – afin d’évaluer si l’oxymétrie de pouls était une 
intervention de santé rentable. Pour tester la solidité de nos résultats, 
nous avons effectué des analyses de sensibilité.
Résultats Avec les prix de 2013, les oxymètres à poser et les oxymètres 
portatifs présentaient des coûts annuels de 310 et 95 dollars, 
respectivement. En supposant que les deux types d’oxymètre ont une 
efficacité identique, un seul oxymètre utilisé pour 22 interventions par 
semaine permettait d’éviter 0,83 EVCI par an. Les oxymètres à poser 
et les oxymètres portatifs coûtaient 374 $ et 115 $ par EVCI évitée, 
respectivement. Pour tous les pays avec un PIB par habitant supérieur 
à 677 $, l’oxymètre portatif s’est avéré rentable s’il évitait seulement 
1,7% des décès liés à l’anesthésie ou 0,3% de mortalité périopératoire. 
Conclusion L’oxymétrie de pouls est une intervention rentable pour 
les pays à faible revenu.
Резюме
Периоперационная пульсовая оксиметрия в странах с низким уровнем доходов: анализ экономической 
эффективности
Цель Оценить экономическую эффективность пульсоксиметрии 
— в сравнении с отсутствием периоперационного мониторинга 
— при проведении операций в странах с низким уровнем 
доходов.
Методы Было рассмотрено использование как настольных, так и 
портативных ручных пульсоксиметров среди пациентов любого 
возраста, перенесших обширное опреативное вмешательство, в 
странах с низким уровнем доходов. Данные об исходном уровне 
смертности и эффективности пульсоксиметров для снижения 
смертности были получены из предыдущих исследований. 
Учитывались прямые затраты на приобретение и обслуживание 
пульсоксиметров, а также стоимость дополнительного 
кислорода, используемого для устранения эпизодов гипоксии, 
выявленных с помощью оксиметрии. Полезность для здоровья 
определялась спасенными годами жизни, скорректированными 
на инвалидность (индекс DALY), при этом полученные значения 
полезности и затрат снижались на 3% в год. Были использованы 
рекомендованные пороговые значения показателя «затраты-
эффективность» — как абсолютные, так и относительные, с 
учетом валового внутреннего продукта (ВВП) на душу населения 
— для оценки того, является ли пульсоксиметрия экономически 
эффективной лечебной мерой. Чтобы проверить надежность 
полученных результатов, был проведен анализ чувствительности.
Результаты Было установлено, что в ценах 2013 года годовые 
затраты на использование настольных и ручных оксиметров 
составили 310 и 95 долларов США соответственно. Если 
предположить, что два типа оксиметров имеют одинаковую 
эффективность, то один оксиметр, применяемый для 22 процедур 
в неделю, спас 0,83 DALY за год. Стоимость настольного и ручного 
оксиметра на спасенный DALY составила 374 и 115 долларов 
США соответственно. Для любой страны с ВВП на душу населения 
свыше 677 долларов США использование ручного оксиметра 
оказалось экономически эффективным, если он позволял 
предотвращать как минимум 1,7% анестезиологических или 0,3% 
периоперационных смертей. 
Вывод Пульсоксиметрия является экономически эффективной 
лечебной мерой для стран с низким уровнем доходов.
Resumen
La oximetría de pulso perioperatoria en los países de ingresos bajos: un análisis de la rentabilidad
Objetivo Evaluar la rentabilidad de la oximetría de pulso en comparación 
con la ausencia de vigilancia perioperatoria durante la cirugía en países 
de ingresos bajos.
Métodos Se tuvieron en cuenta oxímetros de pulso manuales, tanto de 
mesa como portátiles, entre los pacientes de todas las edades sometidos 
a una intervención quirúrgica importante en países de ingresos bajos. 
A partir de los estudios anteriores se obtuvo la mortalidad inicial y 
la eficacia de los oxímetros de pulso para reducir la mortalidad. Se 
consideraron los costes directos de la adquisición y del mantenimiento 
de los oxímetros de pulso, así como el coste del oxígeno complementario 
que se utiliza para tratar los episodios de hipoxia identificados mediante 
la oximetría. Se midieron los beneficios para la salud en años de vida con 
discapacidad (AVAD) evitados, mientras que los beneficios y los costes 
se descontaron al 3% por año. Utilizamos los umbrales de rentabilidad 
recomendados, tanto absolutos como relativos, respecto al producto 
interno bruto (PIB) per cápita para evaluar si la oximetría de pulso es 
una intervención de salud rentable. Por último, se realizó un análisis de 
sensibilidad para poner a prueba la solidez de los resultados.
Resultados En 2013, se halló que los precios de los oxímetros de 
mesa y portátiles suponían unos costes anuales de 310 y 95 dólares 
estadounidenses (US$), respectivamente. En el supuesto de que 
ambos tipos de oxímetro tengan la misma eficacia, el uso de un único 
oxímetro para 22 procedimientos por semana evitó 0,83 AVAD por 
año. Los oxímetros de mesa y manuales cuestan 374 US$ y 115 US$ 
por AVAD evitado, respectivamente. Para cualquier país con un PIB per 
cápita superior a 677 US$ el oxímetro manual resultó ser rentable con 
tan solo impedir un 1,7% de las muertes relacionadas con la anestesia 
o el 0,3% de la mortalidad perioperatoria. 
Conclusión La oximetría de pulso es una intervención rentable para 
entornos de ingresos bajos.Bull World Health Organ 2014;92:858–867| doi: http://dx.doi.org/10.2471/BLT.14.137315 866
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